Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Pharma Industry Analysis

UpdatedApr 11, 2026
DataAggregated Company Financials
Companies23
  • 7D4.8%
  • 3M-21.4%
  • 1Y-8.6%
  • YTD-16.7%

The Pharma industry is up 4.8% in the last week, with Camurus up 6.4%. In contrast, the industry has lost 8.6% in the last 12 months. Looking forward, earnings are forecast to grow by 35% annually.

Industry Valuation and Performance

Has the Swedish Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 11 Apr 2026SEK 43.5bSEK 5.3b-SEK 1,376,536,671.0060.4x-31.6x8.3x
Mon, 09 Mar 2026SEK 41.3bSEK 5.3b-SEK 1,377,968,671.0054.6x-30x7.8x
Wed, 04 Feb 2026SEK 51.1bSEK 5.3b-SEK 1,000,645,157.0055.1x-51.1x9.6x
Fri, 02 Jan 2026SEK 49.9bSEK 5.3b-SEK 531,735,157.0072.3x-93.8x9.4x
Sun, 30 Nov 2025SEK 50.0bSEK 5.3b-SEK 523,264,021.0071.4x-95.6x9.4x
Tue, 28 Oct 2025SEK 50.9bSEK 5.1b-SEK 433,356,865.0076.6x-117.5x9.9x
Thu, 25 Sep 2025SEK 54.5bSEK 5.1b-SEK 405,183,865.0069.6x-134.5x10.7x
Sat, 23 Aug 2025SEK 56.6bSEK 5.1b-SEK 327,043,676.0079.2x-172.9x11.1x
Mon, 21 Jul 2025SEK 57.5bSEK 5.0b-SEK 347,188,364.0069.2x-165.7x11.4x
Wed, 18 Jun 2025SEK 49.7bSEK 4.8b-SEK 574,344,160.2866.5x-86.6x10.3x
Fri, 16 May 2025SEK 46.6bSEK 4.8b-SEK 603,406,964.9063.9x-77.2x9.6x
Sun, 13 Apr 2025SEK 45.9bSEK 4.7b-SEK 807,022,812.2265.7x-56.9x9.7x
Tue, 11 Mar 2025SEK 49.4bSEK 4.7b-SEK 809,467,746.1673x-61x10.5x
Thu, 06 Feb 2025SEK 51.9bSEK 4.4b-SEK 809,643,207.74133.9x-64.1x11.7x
Sat, 04 Jan 2025SEK 51.5bSEK 4.4b-SEK 615,648,418.17130.2x-83.6x11.6x
Mon, 02 Dec 2024SEK 51.1bSEK 4.4b-SEK 617,911,730.25126.9x-82.7x11.5x
Wed, 30 Oct 2024SEK 52.6bSEK 4.3b-SEK 686,768,690.13142.8x-76.6x12.1x
Fri, 27 Sep 2024SEK 65.0bSEK 5.9b-SEK 1,169,874,226.06170.6x-55.6x11x
Sun, 25 Aug 2024SEK 68.9bSEK 5.9b-SEK 939,207,156.0688.7x-73.4x11.7x
Tue, 23 Jul 2024SEK 68.1bSEK 5.5b-SEK 997,535,971.21115.3x-68.3x12.3x
Thu, 20 Jun 2024SEK 63.0bSEK 6.4b-SEK 862,342,259.7571.7x-73.1x9.9x
Sat, 18 May 2024SEK 53.4bSEK 6.4b-SEK 767,607,267.7571.8x-69.6x8.4x
Mon, 15 Apr 2024SEK 51.3bSEK 6.2b-SEK 1,040,626,304.1977.9x-49.3x8.2x
Wed, 13 Mar 2024SEK 50.6bSEK 6.2b-SEK 1,038,034,723.1675.6x-48.8x8.1x
Fri, 09 Feb 2024SEK 52.8bSEK 6.0b-SEK 861,697,426.1267.4x-61.2x8.8x
Sun, 07 Jan 2024SEK 69.1bSEK 9.4b-SEK 1,184,310,332.0064.2x-58.3x7.3x
Tue, 05 Dec 2023SEK 62.7bSEK 9.5b-SEK 1,209,395,296.0057.3x-51.8x6.6x
Thu, 02 Nov 2023SEK 52.8bSEK 9.3b-SEK 1,115,144,896.0080x-47.3x5.7x
Sat, 30 Sep 2023SEK 51.1bSEK 9.2b-SEK 1,177,239,896.00122.3x-43.4x5.6x
Mon, 28 Aug 2023SEK 50.3bSEK 9.2b-SEK 1,128,230,548.00140.6x-44.6x5.5x
Wed, 26 Jul 2023SEK 51.1bSEK 8.8b-SEK 1,369,989,709.0075.6x-37.3x5.8x
Fri, 23 Jun 2023SEK 48.4bSEK 8.4b-SEK 1,693,052,641.0077x-28.6x5.8x
Sun, 21 May 2023SEK 48.2bSEK 8.4b-SEK 1,756,674,031.0082.6x-27.4x5.8x
Tue, 18 Apr 2023SEK 46.1bSEK 8.0b-SEK 1,794,944,413.0091.7x-25.7x5.8x
Price to Earnings Ratio

-25.7x


Total Market Cap: SEK 46.1bTotal Earnings: -SEK 1,794,944,413.00Total Revenue: SEK 8.0bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Pharma Industry Price to Earnings3Y Average -73.7x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 9.1x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 13% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market4.42%
Healthcare2.34%
Pharma4.81%
Pharma4.81%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
CAMX CamurusSEK 514.506.4%
+SEK 1.8b		-5.4%PE41.8x
SECARE SwedencareSEK 27.408.7%
+SEK 351.7m		-22.3%PE78.9x
KLAR Klaria Pharma Holding AB (publ.)SEK 1.2228.2%
+SEK 65.9m		4.7%PS33.4x
IRLAB A IRLAB TherapeuticsSEK 1.569.4%
+SEK 11.4m		-77.8%PS2.3x
CINPHA Cinclus Pharma HoldingSEK 16.440.9%
+SEK 6.5m		49.5%PS13.3x

Latest News

ORX
SEK 20.95
Orexo
7D
-5.8%
1Y
49.6%

ORX: Steady Margins And Elevated P/E Multiple Will Support Future Upside Potential

Analysts have kept their SEK price target for Orexo broadly steady, with only a marginal adjustment that reflects slightly revised views on long term profit margins and the future P/E multiple, while leaving fair value, discount rate, and revenue growth assumptions effectively unchanged. Valuation Changes Fair Value: SEK 38.0 per share, effectively unchanged from the previous SEK 38.
ENZY
SEK 3.01
Enzymatica
7D
-2.3%
1Y
-11.5%
KLAR
SEK 1.22
Klaria Pharma Holding AB (publ.)
7D
28.2%
1Y
4.7%
MOB
SEK 10.08
Moberg Pharma
7D
-4.0%
1Y
42.5%

MOB: Dual Terbinafine Sourcing Will Support Future Re Rating Potential

Analysts have reaffirmed their price target for Moberg Pharma at SEK 13.0 per share, citing unchanged views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Regulators have approved an additional supplier of terbinafine for MOB-015, Moberg Pharma's drug for nail fungus, after a process that started in April 2024 (Key Developments).
CAMX
SEK 514.50
Camurus
7D
6.4%
1Y
-5.4%

CAMX: FDA Review Of Resubmitted NDA Will Drive Future Upside

Analysts have trimmed their 12 month price target for Camurus from SEK 660 to SEK 610, citing updated assumptions that include revised revenue growth, profit margin and future P/E expectations. What's in the News Camurus issued earnings guidance for 2026, with expected revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b, framed against internal 2025 expectations (Key Developments).
IBT B
SEK 49.75
Infant Bacterial Therapeutics
7D
0.7%
1Y
-10.8%
ACUC
SEK 0.76
AcuCort
7D
2.0%
1Y
-9.9%
SECARE
SEK 27.40
Swedencare
7D
8.7%
1Y
-22.3%
PILA
SEK 1.89
Pila Pharma
7D
-9.6%
1Y
-38.3%
FLERIE
SEK 28.80
Flerie
7D
-3.0%
1Y
-28.5%
ONCOZ
SEK 6.00
OncoZenge
7D
5.3%
1Y
17.4%
IRLAB A
SEK 1.56
IRLAB Therapeutics
7D
9.4%
1Y
-77.8%
CESSA
DKK 16.90
Cessatech
7D
-5.8%
1Y
104.1%
ALZCUR
SEK 1.47
AlzeCure Pharma
7D
-13.5%
1Y
-39.8%
CINPHA
SEK 16.44
Cinclus Pharma Holding
7D
0.9%
1Y
49.5%
DICOT
SEK 0.39
Dicot Pharma
7D
-6.9%
1Y
45.0%

Is Dicot Pharma (STO:DICOT) In A Good Position To Invest In Growth?

Feb 03
Is Dicot Pharma (STO:DICOT) In A Good Position To Invest In Growth?